Oscar Ignacio Cabezas

Dr. Oscar Ignacio Cabezas

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2022 in Animals
Verified
Journal Article
Open access
PDF file
MRMiguel Angel Gutiérrez Reinoso
Miguel Angel Gutiérrez Reinoso
CAConstanza Aguilera
Constanza Aguilera
FNFelipe Navarrete
Felipe Navarrete
JCJoel Cabezas
Joel Cabezas
Fidel ovidio CastroFidel ovidio Castro
Fidel ovidio Castro
LRLleretny Rodriguez-Alvarez
Lleretny Rodriguez-Alvarez
Over the last few years, several commercial FSH products have been developed for cattle superovulation (SOV) purposes in Multiple Ovulation and Embryo Transfer (MOET) programs. The SOV response is highly variable among individuals and remains one of the main limiting factors in obtaining a profitable number of transferable embryos. In this study, follicle stimulating hormone (FSH) from different origins was included in two SOV protocols, (a) FSH from purified pig pituitary extract (NIH-FSH-p; two doses/day, 12 h apart, four consecutive days); and (b) extra-long-acting bovine recombinant FSH (bscrFSH; a single dose/day, four consecutive days), to test the effects of bscrFSH on the ovarian response, hormone profile levels, in vivo embryo production and the pluripotency gene expression of the obtained embryos. A total of 68 healthy primiparous red Angus cows (Bos taurus) were randomly distributed into two experimental groups (n = 34 each). Blood sample collection for progesterone (P4) and cortisol (C) level determination was performed together with ultrasonographic assessment for ovarian size, follicles (FL) and corpora lutea (CL) quantification in each SOV protocol (Day 0, 4, 8, and 15). Moreover, FSH profiles were monitorised throughout both protocols (Day 0, 4, 5, 6, 7, 8, 9, 10, and 15). In vivo embryo quantity and quality (total structures, morulae, blastocysts, viable, degenerated and blocked embryos) were recorded in each SOV protocol. Finally, embryo quality in both protocols was assessed by the analysis of the expression level of crucial genes for early embryo development (OCT4, IFNt, CDX2, BCL2, and BAX). P4 and cortisol concentration peaks in both SOV protocols were obtained on Day 15 and Day 8, respectively, which were statistically different compared to the other time-points (p < 0.05). Ovarian dimensions increased from Day 0 to Day 15 irrespective of the SOV protocol considered (p < 0.05). Significant changes in CL number were observed over time till Day 15 irrespective of the SOV protocol applied (p < 0.05), being non- significantly different between SOV protocols within each time-point (p > 0.05). The number of CL was higher on Day 15 in the bscrFSH group compared to the NIH-FSH-p group (p < 0.05). The number of embryonic structures recovered was higher in the bscrFSH group (p = 0.025), probably as a result of a tendency towards a greater number of follicles developed compared to the NIH-FSH-p group. IFNt and BAX were overexpressed in embryos from the bscrFSH group (p < 0.05), with a fold change of 16 and 1.3, respectively. However, no statistical differences were detected regarding the OCT4, CDX2, BCL2, and BCL2/BAX expression ratio (p > 0.05). In conclusion, including bscrFSH in SOV protocols could be an important alternative by reducing the number of applications and offering an improved ovarian response together with better embryo quality and superior performance in embryo production compared to NIH-FSH-p SOV protocols.

28 March 2023 in Animal Reproduction Science
Verified
Journal Article
Closed access
MGMiguel A. Gutiérrez-Reinoso
Miguel A. Gutiérrez-Reinoso
CACesar J. Arreseigor
Cesar J. Arreseigor
BDBrian Driedger
Brian Driedger
OCOscar Ignacio Cabezas
Oscar Ignacio Cabezas
FHFlorence Hugues
Florence Hugues
Manuel Garcia-HerrerosManuel Garcia-Herreros
Manuel Garcia-Herreros

Verified
Journal Article
Open access
PDF file
VAVerónica Avello
Verónica Avello
SSSantiago Alberto Salazar
Santiago Alberto Salazar
EHEddy Ernesto González Horta
Eddy Ernesto González Horta
PMPaula Canpos Martínez
Paula Canpos Martínez
Viana Manrique SuárezViana Manrique Suárez
Viana Manrique Suárez
RMRaquel Montesino
Raquel Montesino
Multivalent live-attenuated or inactivated vaccines are often used to control the bovine viral diarrhea disease (BVD). Still, they retain inherent disadvantages and do not provide the expected protection. This study developed a new vaccine prototype, including the external segment of the E2 viral protein from five different subgenotypes selected after a massive screening. The E2 proteins of every subgenotype (1aE2, 1bE2, 1cE2, 1dE2, and 1eE2) were produced in mammalian cells and purified by IMAC. An equimolar mixture of E2 proteins formulated in an oil-in-water adjuvant made up the vaccine candidate, inducing a high humoral response at 50, 100, and 150 µg doses in sheep. A similar immune response was observed in bovines at 50 µg. The cellular response showed a significant increase in the transcript levels of relevant Th1 cytokines, while those corresponding to the Th2 cytokine IL-4 and the negative control were similar. High levels of neutralizing antibodies against the subgenotype BVDV1a demonstrated the effectiveness of our vaccine candidate, similar to that observed in the sera of animals vaccinated with the commercial vaccine. These results suggest that our vaccine prototype could become an effective recombinant vaccine against the BVD.

22 October 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TRThelvia Isabel Ramos
Thelvia Isabel Ramos
CVCarlos Villacís
Carlos Villacís
FSFelipe Sandoval
Felipe Sandoval
Sarah Martin-SolanoSarah Martin-Solano
Sarah Martin-Solano
Viana Manrique SuárezViana Manrique Suárez
Viana Manrique Suárez
JTJorge Roberto Toledo
Jorge Roberto Toledo
Background: Interferons (IFNs) are cytokines involved in the immune response with a synergistic regulatory effect on the immune response. They are therapeutics for various viral and proliferative conditions, with proven safety and efficacy. Their clinical application is challenging due to the molecules’ size, degradation, and pharmacokinetics. We are working on new drug delivery systems that provide adequate therapeutic concentrations for these cytokines and prolong their half-life in the circulation, such as nanoformulations. Methods: Through nanoencapsulation using electrospray technology and biocompatible and biodegradable polymers, we are developing a controlled release system based on nanoparticles for viral infections of the respiratory tract. Results: We developed a controlled release system for viral respiratory tract infections. A prototype nanoparticle with a core was created, which hydrolyzed the polyvinylpyrrolidone (PVP) shell , releasing the active ingredients interferon-alpha (IFN-α) and interferon-gamma (IFN-γ). The chitosan (QS) core degraded slowly, with a controlled release of IFN-α. The primary and rapid effect of the interferon combination ensured an antiviral and immunoregulatory response from day one, induced by IFN-α and enhanced by IFN-γ. The multilayer design demonstrated an optimal toxicity profile. Conclusions: This formulation is an inhaled dry powder intended for the non-invasive intranasal route. The product does not require a cold chain and has the potential for self-administration in the face of emerging viral infections. This novel drug has applications in multiple infectious, oncological, and autoimmune conditions, and further development is proposed for its therapeutic potential. This prototype would ensure greater bioavailability, controlled release, fewer adverse effects, and robust biological action through the simultaneous action of both molecules.

1 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TRThelvia Isabel Ramos
Thelvia Isabel Ramos
CVCarlos Villacís
Carlos Villacís
FSFelipe Sandoval
Felipe Sandoval
Sarah Martin-SolanoSarah Martin-Solano
Sarah Martin-Solano
Viana Manrique SuárezViana Manrique Suárez
Viana Manrique Suárez
JTJorge Roberto Toledo
Jorge Roberto Toledo
Interferons (IFNs) are cytokines involved in the immune response with synergistic regulatory action. They are therapeutics for various viral and proliferative conditions, with proven safety and efficacy. Their clinical application presents difficulties due to the molecules' size, degradation, and pharmacokinetics. We developed a controlled release system for viral respiratory tract infections. A core-shell nanoparticle was prototyped, which hydrolyzed the shell (polyvinylpyrrolidone), releasing the active ingredients IFN-α and IFN-γ. The core (chitosan) degraded slowly, with a controlled release of IFN-α. The primary and rapid effect of the combination of interferons ensured an antiviral and immunoregulatory response from day one, induced by IFN-α and enhanced by IFN-γ. The multilayer design demonstrated an optimal toxicity profile. This formulation is an inhaled dry powder targeted for the non-invasive intranasal route. This prototype would ensure greater bioavailability, controlled release, fewer adverse effects, and robust biological action thanks to the simultaneous impact of both molecules.

3 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ELEmilio Lamazares
Emilio Lamazares
AVAleikar Vásquez-Suárez
Aleikar Vásquez-Suárez
KGKelly Gancino
Kelly Gancino
FSFelipe Sandoval
Felipe Sandoval
JYJaviera Yáñez-Torres
Javiera Yáñez-Torres
JTJorge Roberto Toledo
Jorge Roberto Toledo
Early embryonic loss is a significant cause of reproductive inefficiency and economic loss in cattle, largely due to inadequate maternal recognition of pregnancy and premature luteolysis. Interferon tau (IFN-τ), a trophoblast-derived signaling molecule, is essential for maintaining corpus luteum function and embryo survival in ruminants, but its rapid degradation and short half-life have limited its practical use. This study developed a novel delivery system for bovine recombinant IFN-τ (brIFN-τ) produced in Pichia pastoris, utilizing chitosan-based microencapsulation and starch-chitosan hydrogels for sustained intrauterine release. The recombinant protein was successfully expressed, purified, and structurally validated, confirming its interaction with bovine interferon receptors. Encapsulated IFN-τ showed controlled, prolonged in vitro release and retained biological activity, demonstrated by increased viability and antiviral response in bovine cells exposed to Mengo virus. In vivo, the microencapsulated formulation was safe and effectively inhibited luteolysis, as shown by sustained progesterone levels and reduced corpus luteum regression compared to controls. These results indicate that hydrogel-delivered, microencapsulated brIFN-τ is a promising biotechnological strategy to modulate luteolysis, enhance maternal recognition of pregnancy, and reduce early embryonic loss in cattle, potentially improving reproductive efficiency and supporting more sustainable livestock management.